APA (7th ed.) Citation

Han, B., Li, K., Chu, T., Bi, M., Zhang, H., Yu, Y., . . . Han, C. (2018). 396OA multi-center, randomized, double-blind, parallel, two-group phase III trial on the efficacy and safety of QL1101 or bevacizumab in combination with paclitaxel and carboplatin in first-line treatment of non-squamous non-small cell lung cancer. Annals of Oncology, 29, N.PAG. https://doi.org/10.1093/annonc/mdy442

Chicago Style (17th ed.) Citation

Han, B., et al. "396OA Multi-center, Randomized, Double-blind, Parallel, Two-group Phase III Trial on the Efficacy and Safety of QL1101 or Bevacizumab in Combination with Paclitaxel and Carboplatin in First-line Treatment of Non-squamous Non-small Cell Lung Cancer." Annals of Oncology 29 (2018): N.PAG. https://doi.org/10.1093/annonc/mdy442.

MLA (9th ed.) Citation

Han, B., et al. "396OA Multi-center, Randomized, Double-blind, Parallel, Two-group Phase III Trial on the Efficacy and Safety of QL1101 or Bevacizumab in Combination with Paclitaxel and Carboplatin in First-line Treatment of Non-squamous Non-small Cell Lung Cancer." Annals of Oncology, vol. 29, 2018, p. N.PAG, https://doi.org/10.1093/annonc/mdy442.